Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
We have prospectively evaluated the risk of incident coronary events in association with serum total homocysteine in patients with preexisting chronic coronary heart disease. A nested case-control design was used. Total homocysteine concentration was measured in baseline fasting serum samples from patients with chronic coronary heart disease enrolled in the Bezafibrate Infarction Prevention Study (n = 3,090) who developed coronary events during 6.2 years of follow-up (n = 69). They were matched for age and gender with controls without subsequent cardiovascular events. Elevated homocysteine levels were associated with 2.5 times higher risk of subsequent coronary events and each 5 mumol/l increment was associated with a 25% higher risk.
Haim
Moti
M
Department of Cardiology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel. motih@netvision.net.il
Tanne
David
D
Goldbourt
Uri
U
Doolman
Ram
R
Boyko
Valentina
V
Brunner
Daniel
D
Sela
Ben-Ami
BA
Behar
Solomon
S
D001629:Bezafibrate / Q000627:therapeutic use; D016022:Case-Control Studies; D003327:Coronary Disease / Q000097:blood*; D016757:Death, Sudden, Cardiac; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000517:prevention & control; D011446:Prospective Studies; D012307:Risk Factors
D000960:Hypolipidemic Agents; D006710:Homocysteine; D001629:Bezafibrate